This is a review of the use of empagliflozin/linagliptin in treating type 2 diabetes. The review covers pharmacological properties, efficacy, safety and potential advantages, and key studies featuring this medicine’s use.
Commentary has been provided by Dr Michael d’Emden, who is Director of the Department of Endocrinology and Diabetes, Royal Brisbane Hospital, a Clinical Associated Professor of the University of Queensland and previous vice president of the Australian Diabetes Society.
Please login below to download this issue (PDF)